Enanta Pharmaceuticals Inc

9EP

Company Profile

  • Business description

    Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.

  • Contact

    4 Kingsbury Avenue
    WatertownMA02472
    USA

    T: +1 617 607-0800

    E: [email protected]

    https://www.enanta.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    30 September 2026

    Employees

    120

Stocks News & Analysis

stocks

Nvidia earnings: Another stellar quarter with no signs of a slowdown

Nvidia remains at the heart of the AI ecosystem.
stocks

Chart of the Week: Software selloff creates opportunity for these two stocks

Can AI disrupt the software business model?
stocks

Market is misinterpreting AI impact on cheap ASX share

Unwarranted sell-off with shares down by half in three months.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,408.7027.40-0.29%
CAC 408,624.5665.490.77%
DAX 4025,290.99115.050.46%
Dow JONES (US)49,482.15307.650.63%
FTSE 10010,822.3315.920.15%
HKSE26,381.02384.70-1.44%
NASDAQ23,152.08288.391.26%
Nikkei 22558,753.39170.270.29%
NZX 50 Index13,670.71145.131.07%
S&P 5006,946.130.000.00%
S&P/ASX 2009,175.3027.60-0.30%
SSE Composite Index4,146.630.60-0.01%

Market Movers